INTRODUCTION
In 1970, during a study of immunological mechanisms involving histamine and serotonin release from platelets in immunized rabbits, Henson [1] proposed that 'a soluble factor' was released from leukocytes which stimulated platelets to release vasoactive amines. This observation was confirmed independently by Siraganian and Osler [2] in 1971. In 1972, Benveniste, Henson and Cochrane [3] demonstrated that the antibody involved in the immunological reaction described above was an IgE class antibody and coined the term 'platelet-activating factor (PAF)' for the soluble factor released from basophils following IgE stimulation. Several reports followed describing the lipid character of PAF [4] [5] [6] . However, it was not until 1979 that Demopoulos, Pinckard and Hanahan [7] demonstrated that a semisynthetic phosphoacylglycerol, l-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC), had physiochemical as well as biological properties (i.e. aggregation ofplatelets and secretion of serotonin) indistinguishable from those of naturally-generated PAF [6] . At the same time, Blank et al. [8] reported independently the preparation of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine from choline plasmalogens isolated from bovine heart by using the same semisynthetic approach used by Demopoulos et al. [7] . The compound synthesized by Blank et al. possessed profound antihypertensive properties in the rat. Shortly after these events, Benveniste et al. [9] reported the chemical preparation of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine, which had similar biological properties to those of naturally-occuring PAF. After these initial attempts to characterize the chemical structure of PAF, Hanahan et al. [10] isolated PAF from sensitized rabbit basophils and characterized the chemical structure of the naturally-occuring substance by using gas-liquid chromatography and mass spectral analysis and demonstrated that naturally-occuring PAF was indeed AGEPC. The structure of this novel ether lipid is shown in Figure 1 .
Several important features ofthis phosphoacylglyerol mediator were revealed through evaluation of the functional capacities of structural analogues of PAF (reviewed in [11, 12] ). PAF has an 0-alkyl ether residue at the sn-I position and a short acyl chain, i.e. an acetyl moiety, at the sn-2 position. The sn-3 position is occupied by the polar head group 0-phosphocholine. Several modifications, such as (a) acyl analogues at the sn-I position, (b) different chain lengths of the ester group beyond three carbon atoms or a hydroxyl group at the sn-2 position, and (c) ethanolamine substituted for choline at the sn-3 position, greatly diminish or even abolish biological activity.
During the past decade, the elucidation of the biological properties of PAF has indicated that this molecule is involved extensively in intercellular signalling in a variety of pathophysiological situations. Numerous cell types and tissues have been shown to synthesize and release PAF upon stimulation and at the same time to exhibit biological responses to this compound ( Table 1 ). There are two metabolic pathways involved in the biosynthesis of PAF, the remodelling and the de novo pathways. The details of the synthetic and degradative pathways for PAF [11, 12, [17] [18] [19] . This article will discuss the characterization and regulation of the PAF receptor and PAF receptor-mediated transmembrane signalling mechanisms.
are summarized in Figure 2 . Ligand binding studies indicate that specific PAF receptors can be identified in various cells and tissues (reviewed in [13] [25] , neutrophils [26] [27] [28] , macrophages [29, 30] , mononuclear leukocytes [31] , eosinophils [32] , and Kupffer cells [33] . In neutrophils, there exist two classes of binding sites [26] [27] [28] 34] , high-and low-affinity ( Figure 3 Schematic representation of PAF receptor Guinea pig lung PAF receptor has 342 amino acids and a molecular mass of 38982. There are seven transmembrane segments. The possible intracellular phosphorylation sites of the PAF receptor [14] are illustrated. S, serine residues; T, threonine residues; Y, tyrosine residues.
was the observation that both electrical and chemical stimulation of either the isolated perfused rat brain or the brain of an intact animal resulted in a substantial increase in PAF levels in the brain [39] . Such observations suggest an important role(s) for PAF in the brain under various physiological and pathophysiological situations. Supporting this suggestion was an investigation conducted by Domingo et al. [40] [42] .
Early attempts to purify and to characterize PAF receptor proteins from different sources, mainly from rabbit and human platelets [43] [44] [45] have been unsuccessful. Using photoaffinity labelling techniques, PAF binding proteins in rabbit platelet membranes have been characterized [46] . A photoreactive, radioiodinated derivative of PAF, 1-0-(4-azido-2-hydroxy-3-iodobenzamido)undecyl -2 -0 -acetyl -sn -glycero - [14] . The cloning strategy involved the construction of a cDNA library from size-fractionated poly(A) RNA, the synthesis of a transcript of the cDNA in vitro using phage DNA as a template, the expression of the transcript in Xenopus oocytes, and the electrophysiological detection of a PAF-induced response in the oocytes. The PAF receptor cDNA analysis indicated that the PAF receptor has 342 amino acids and a molecular mass of 38982 Da. A hydropathy profile analysis suggested the existence of seven transmembrane segments and the cytoplasmic tail of the PAF receptor contained four serine and five threonine residues as possible phosphorylation sites ( Figure 3 ). Subsequently, the PAF receptor was cloned from human leukocytes [15, 47] and from HL-60 granulocytes [16] . The cloned PAF receptor from human leukocytes has similar characteristics to that of guinea pig lung with 83 % identity in the amino acid sequence. Using the expressed PAF receptor in Xenopus laevis oocytes and COS-7 cells, it was demonstrated that the PAF receptor is linked functionally to phosphoinositide metabolism via a G-protein [15] .
Linkage with guanine nucleotide regulatory proteins Numerous studies have indicated that PAF receptor-induced transmembrane signalling mechanisms involve guanine nucleotide regulatory proteins (G-proteins). Although it is clear that the PAF receptor is coupled to various cellular effector systems such as phospholipase A2 and phospholipase C through Gproteins, the identities of the G-proteins involved have not been characterized.
The initial observations concerning the involvement of Gproteins in PAF action were made in the early 1980s. It was found that synthetic PAF inhibited adenylate cyclase activity in the particulate fraction ofplatelets [48, 49] and stimulated GTPase activity as well [49] [50] [51] [52] [53] . In an effort to elucidate the identity and properties of G-protein(s) involved involving proteolytic digestion of the G-protein and subsequent two-dimensional electrophoresis, it was concluded that in platelets a single pertussis toxin-sensitive, ac4-containing G-protein was invoved in the regulation of both adenylate cyclase and phospholipase C. In rabbit platelets, PAF receptor stimulation increased GTPase activity [51, 52] and this stimulatory effect of PAF on GTPase activity was attenuated in cells pretreated with phorbol ester, dibutyryl cyclic AMP, and by PAF-induced desensitization [51] . It is likely that both homologous desensitization [55] and dibutyryl cyclic AMP [56] modify PAF receptors causing functional dissociation of PAF receptors from their G-proteins. On the other hand, phorbol ester was found to suppress PAF-mediated signal transduction through modification of the GTP-binding proteins, as phorbol ester was found to abolish PAF-stimulated GTPase activity [51] . This observation suggests that protein kinase C selectively inhibits PAF effects by inactivating a GTP-binding protein coupled with PAF receptors, although activation of protein kinase C also down-regulates surface PAF receptors [57] [58] [59] .
Although evidence has been presented that GTP-binding protein(s) are involved in signal transduction from PAF receptors to a receptor-stimulated phospholipase A2, the identity and properties of the G-protein regulating the activity of phospholipase A2 remain uncertain. Pertussis toxin inhibits PAF-elicited arachidonic acid release, PGE2 formation, and inositol trisphosphate production, but it does not alter significantly the rise in intracellular calcium [60] . Further information concerning the G-protein regulation of phospholipase A2 was presented by Nakashima et al. [61] in neutrophils and Kajiyama et al. [62] in rabbit platelets. In neutrophils permeabilized with saponin, the guanine nucleotide analogue guanosine 5-[3-O-thio]triphosphate (GTPyS) and NaF, which bypass receptors and directly activate G-proteins, induced the release of [3H]arachidonic acid. The effect of GTPyS was inhibited by pretreatment with pertussis toxin. Similar information was obtained from a human neutrophil homogenate and membrane preparation [63] and in platelets [62] . GTPyS, guanosine 5-[fly-imido]triphosphate and NaAlF4 all caused a significant release of arachidonic acid in digitonin-permeabilized platelets. The stimulatory effect of the GTP analogues was inhibited by guanosine 5-[2-Othio]diphosphate and by pertussis toxin.
Interestingly, GTP-binding proteins may be involved in PAFstimulated release of PAF. PAF enhanced the release of newly synthesized PAF in human neutrophils, as assessed by [3H]acetate incorporation into PAF. The non-metabolizable bioactive PAF analogue 1-O-hexadecyl-2-(N-methyl)-carbamoyloxy-snglycero-3-phosphocholine [64] , but not lyso-PAF, enhanced the release of newly-synthesized PAF. The PAF-stimulated PAF release was inhibited in pertussis toxin-treated neutrophils. The biosynthesis of PAF involves activation of at least two critical enzymes, phospholipase A2 and the PAF acetyltransferase. The observation that pertussis toxin inhibits the PAF-stimulated synthesis of PAF suggests that a G-protein is likely to be involved in the signal transduction from PAF receptors to the PAF-synthesizing enzyme system.
Regulation
Knowledge of the regulatory factors that affect specific PAF receptors and subsequently control PAF-elicited cellular responses remains in the initial stages of development. Generally, any factor affecting the process of PAF binding to its receptor or subsequent PAF receptor-mediated signal transduction is a likely candidate as a regulator of specific PAF receptors.
It has been found that PAF down-regulates its own receptors in platelets [20, 21] and in cultured Kupffer cells [55] . Valone et al. [20] showed that pretreatment of human platelets with PAF led to a decrease in specific [3H]PAF binding. The ligand-mediated loss of specific PAF receptors was very rapid, with only 50 % of the specific binding sites remaining after 90 s of incubation at 37 'C. Kloprogge and Akkerman [21] confirmed this finding that desensitized human platelets failed to respond to PAF because of a loss of available binding sites for PAF. However, Chesney et al. [65] reported that pretreatment of human platelets with PAF caused a decrease in the binding affinity of specific PAF receptors rather than the loss of binding sites. In contrast, Homma et al. [66] found, in an investigation of the mechanism for the desentization of PAF responses, that functionally desensitized rabbit platelets did not lose their capacity for specific binding of [3H]PAF. Rather, PAF-treated platelets internalized more [3H]PAF than control platelets. A potential problem with the investigations regarding homologous down-regulation of the PAF receptor was that very little attention was given to the extent to which PAF molecules added during pretreatment associate with the platelet membrane after the pretreatment and any subsequent wash procedure. The presence of residual unlabelled PAF from the pretreatment could decrease subsequent specific [3H]PAF binding. The lack of such information renders data concerning the loss of specific [3H]PAF binding sites difficult to interpret since PAF is very hydrophobic and exhibits high non-specific binding to the lipid bilayer of the plasma membrane. A washing procedure employing a high concentration (1 %) of bovine serum albumin can remove PAF efficiently from the outer leaflet of cells [55] .
In neutrophils [57, 58] and rat Kupffer cells [59] the PAF receptor is modulated by protein kinase C. In neutrophils, specific [3H]PAF receptors were modulated by the protein kinase C activator phorbol ester [57, 58] , as well as by LTB4 [58] . The regulatory effect of protein kinase C on specific PAF receptors was bidirectional, increasing specific [3H]PAF binding at low concentrations and decreasing binding at high concentrations. The protein kinase C regulation of PAF receptors seems to be cell type-dependent since the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) had no effect on specific binding of PAF in rabbit platelets [51] . Although dibutyryl cyclic AMP was reported to have profound inhibitory effects on PAFstimulated biological responses such as platelet aggregation and GTPase activity, cyclic AMP analogues at concentrations as high as 2 mM had little apparent effect on [3H]PAF binding in rabbit platelets [51] . However, in cultured Kupffer cells, prolonged incubation with cyclic AMP analogues or forskolin decreased the surface expression of PAF receptors [56] . In U937 cells, dibutyryl cyclic AMP was found to down-regulate PAF receptor mRNA levels after a 72 h treatment [47] . These observations indicate that cyclic AMP down-regulates surface expression of PAF receptors through a mechanism involving decreased PAF receptor gene expression and/or subsequent receptor protein synthesis.
It is evident that various monovalent and divalent cations exert regulatory effects on PAF receptors. Na+ specifically inhibited [3H]PAF binding at 0°C, primarily due to a decrease in the affinity of specific PAF receptors while Li' was 25-fold less effective and K+, Cs' and Rb+ enhanced PAF binding. Mg2+, Ca2+ and Mn2+ enhanced the specific PAF receptor binding 8-10-fold. Scatchard analysis of the binding data suggested that the Mg2+-induced enhancement of specific PAF binding was attributable to an increase in the affinity of the receptor for PAF and an increase in the available specific PAF binding sites. The specific mechanism involved in these cation effects on PAF receptors has not been elucidated [52] . Zinc ions have been shown to have profound inhibitory effects on PAF-induced activation of rabbit [67] and human [68] platelets, as well as [3H]PAF binding [68] . The decrease in specific [3H]PAF binding caused by zinc resulted primarily from a decreased affinity of the specific binding sites rather than a reduced number of binding sites. Compared with Zn2+, Cd2+ and Cu2+ had much weaker inhibitory effects on specific PAF binding [68] .
Recent studies have demonstrated that bacterial lipopolysaccharide (LPS) induces an increase in the surface expression of PAF receptors in macrophages [69] . Consequently, the PAF-induced increase in intracellular Ca2+ is enhanced [69, 70] . The receptor regulatory effect of LPS is time-dependent with a maximal effect (150-200 %) observed within 5 h and 8 h. Cycloheximide and actinomycin D can abolish the effect of LPS, suggesting the involvement of enhanced receptor protein synthesis and mRNA production in this event [69] . The alteration of PAF receptor expression in response to LPS treatment may represent one of the mechanisms for LPS priming of PAFinduced responses such as prostaglandin E2 production [71] .
PAF-MEDIATED BIOCHEMICAL EFFECTS Arachidonic acid metabolism
During the past decade, a vast literature has been elaborated to define the relationship between PAF action and arachidonic acid metabolism. Various types of cells release arachidonic acid when PAF is synthesized as well as in response to PAF stimulation (Figures 2 and 4) . Moreover, it is known that both PAF and arachidonic acid can be released from a common precursor, 1-0-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine (Figure 2) .
Numerous types of cells and tissues release arachidonic acid and its metabolites in response to PAF stimulation. Responsive cells include platelets [72, 73] , neutrophils [63, [74] [75] [76] , eosinophils [77, 78] , macrophages [33, 56, 59, [79] [80] [81] , smooth muscle cells [82] , epithelial cells [83] , and the perfused heart [84] and liver [85] , to name a few. The released arachidonic acid and its metabolites in response to PAF are believed to play an important role in various physiological and pathophysiological processes.
In an in vivo study, McManus et al. [73] found that intravenous antigen challenge of IgE-sensitized rabbits caused a significant elevation of plasma TXB2. Simultaneously, basopenia, thrombocytopenia and neutropenia occurred. The cyclooxygenase inhibitor aspirin, when given to rabbits 18 h before antigen challenge, did not prevent the development of thrombocytopenia, neutropenia, basopenia, or the release of platelet factor 4, but reduced significantly the release of TXB2 and resulted in mortality in IgE-sensitized rabbits. Based on these observations and data from in vitro experiments where PAF was found to stimulate platelets to synthesize TXB2, serotonin and platelet factor 4, it was suggested that TXB2 release into the circulation during IgE-induced anaphylaxis in the rabbit may result, in part, from PAF stimulation of thromboxane synthesis by circulating rabbit platelets. However, this arachidonic acid metabolite was not necessary to alter circulating blood cells or platelet factor 4 secretion but may have served to reduce the IgE-induced anaphylactic reaction.
In cultured rat mesangial cells, PAF stimulated arachidonic acid release as well as PGE2 synthesis. At the same time, PAF caused contraction of mesangial cells with a dose-response and time-course parallel to that for PGE2 production. The PAFelicited contraction of mesangial cells was enhanced when PGE2 synthesis was inhibited. It was suggested that the production of glomerular prostaglandins may be an important facet of glomerulonephritis [79] .
Arachidonic acid metabolites also play an important role in PAF-induced coronary vasoconstriction and reduced cardiac contractility in the isolated perfused rat heart [84] . Both cyclooxygenase-and lipoxygenase-derived arachidonic acid metabolites were released into the cardiac effluent perfusate in response to PAF challenge. These metabolites of arachidonic acid included PGF20, PGE2, 6-ketoPGFia, TXB2, LTB4 and LTC4. Through the use of inhibitors of lipoxygenase and cyclooxygenase and a leukotriene receptor antagonist, these authors demonstrated that LTC4 released during PAF challenge was largely responsible for the coronary vasoconstriction induced following infusion of PAF. There was no information presented, however, as to whether a PAF receptor antagonist inhibited the cardiac effects of PAF. The possibility that PAF may act directly on target cells causing cardiac haemodynamic changes in the perfused heart was not ruled out [84] .
In human [77] and guinea pig eosinophils [78] , isolated from either the peritoneal cavity or bronchoalveolar lavages, PAF has been found to stimulate synthesis of LTC4, LTB4 and TXB2. Human eosinophils produce primarily LTC4, a powerful airway smooth-muscle constrictor [86] , and 1 5-HETE, a substance thought to be'responsible for excessive airway mucus production [87] . The finding that PAF induces synthesis of leukotrienes from lung cells may explain some of the pathophysiological roles of PAF in allergic respiratory diseases. Supporting this contention was an early observation [88] that PAF-induced rapid pulmonary vasoconstriction and oedema in isolated lungs was mediated through the action of LTD4 and LTC4, which were identified in the lung effluent perfusate after stimulation with PAF. Lipoxygenase-derived products of arachidonic acid also may mediate PAF-induced neutrophil aggregation and release of granule-associated enzymes [74] [75] [76] .
The mechanisms by which PAF stimulates arachidonic acid release have been investigated extensively in various types of cells [56, 63, 80, [89] [90] [91] [92] [93] . Using the relatively non-specific phospholipase A2 inhibitors mepacrine and 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid [63, 71] cellular but not extracellular Ca2+ [63] . In cultured Kupffer cells, however, PAF-induced activation of phospholipase A2 depended on extracellular Ca2+ [33, 93] . In addition, PAF induces activation of phospholipase A2 through a protein kinase Cdependent mechanism [59, 90, 91, 93] . Pertussis toxin pretreatment abolished PAF-induced arachidonic acid release, suggesting a G-protein involvement in this event [60, 63, 90] . The stimulatory effect of PAF on phospholipase A2 may also be regulated by intracellular cyclic AMP levels [56, 92] .
PAF not only stimulates arachidonic acid release from membrane phospholipids but also promotes incorporation of arachidonic acid into phospholipids. PAF stimulated the incorporation of [1-_4C] arachidonic acid in a Ca2+-independent fashion most significantly into phosphatidylinositol and phosphatidylcholine in guinea pig [94] as well as in human neutrophils [95, 96] . Moreover, PAF did not alter the distribution of [1-_4C] arachidonic acid in the various molecular species of phosphatidylcholine (diacyl, alkylacyl and alkenylacyl species) after brief incubation intervals, suggesting that the increased formation of [1-14C] arachidonylphosphatidylcholine was not derived from the added PAF, e.g. alkylacyl-phosphatidylcholine formation with an ether linkage at the sn-I position. The mechanism of the stimulatory effect of PAF on acylation of phospholipids has not been elucidated completely. Both increased fatty acid uptake and increased availability of lysophospholipids following phospholipase A2 activation may contribute to the increased phospholipid acylation induced by PAF [96] . However, other mechanisms such as the increased activity of fatty acylCoA synthetase and acyltransferase, two enzymes essential for the acylation of phospholipids during PAF stimulation, deserve to be considered.
Arachidonic acid can be generated directly or indirectly by agonist activation of phospholipases and may act as a signalling element in various cellular reactions. In addition to serving as a precursor for eicosanoid synthesis, a function which has considerable pathophysiological significance, arachidonic acid has been implicated in a variety of biochemical responses such as activation of protein kinase C and adenylate cyclase, and the regulation of intracellular calcium concentrations [97] . Also, arachidonic acid was found to play an important role in the regulation of K+ channel opening in cardiac and smooth muscle [98] . Moreover, it has been suggested that there exists a regulatory relationship between arachidonic acid and phosphoinositide hydrolysis. It has been demonstrated that arachidonic acid causes a dose-dependent increase in the accumulation of inositol phosphates, including InsP3, InsP2, and InsP, in cultured astrocytes [99] . Inositol phosphate formation following application of carbachol or noradrenaline was additive with arachidonic acid, whereas a similar response evoked by PAF or ATP was not additive with arachidonic acid.
Phosphoinositide turnover
It has become clear that one of the key events in PAF-mediated signalling mechanisms is the hydrolysis of phosphatidylinositol 4,5-bisphosphate, by a specific phospholipase C, yielding two second messengers, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate. DAG was found to activate protein kinase C leading to phosphorylation of various substrates [100, 101] whereas InsP3 mobilizes intracellular calcium [102, 103] (Figure  4) . PAF has been found to stimulate the hydrolysis of phosphatidylinositol in a wide variety of cell types including rabbit [104, 105] , human [106] , and horse [107, 108] platelets, smooth muscle cells [109] , hepatocytes [110, 111] , macrophages [30, 112, 113] , neutrophils [114] , endothelial cells [115] , human keratinocytes [116] , glomerular mesangial cells [60, 117] and Kupffer cells [118, 119] . It was first reported that PAF stimulated metabolism of inositol phospholipids and phosphatidic acid in washed rabbit platelets [104] ; PAF caused a 15-20 % decrease in the PtdIns level within 15 s with a dramatic four-fold increase in phosphatidic acid. The effect of PAF on the metabolism of phosphoinositide was quite specific since other major classes of phospholipids were not affected. If [32P]Pi was present in the medium, PAF enhanced significantly the incorporation of radioactivity into the PtdlnsP, PtdInsP2 and phosphatidic acid fractions within 1 min while the incorporation of [32P]p1 into phosphatidylinositol increased thereafter. In 32P-labelled hepatocytes [110] , PAF, at a concentration of 5 x 10-10 M, caused a 30-40 % decrease in [32P]PtdInsP2 within 10 s. The 32P content of the PtdlnsP and Ptdlns fractions also decreased but at a slower rate. With horse platelets prelabelled with [32P]P , it was shown that PAF initiated a rapid formation of labelled phosphatidic acid followed by an increase in phosphatidylinositol.
PAF has potent stimulatory effects on macrophages [30, 112] . Macrophages stimulated with PAF produced several inositol phosphates, including Ins(1,4,5)P3 and Ins(1,3,4,5)P4, and as a consequence, the intracellular level of calcium was elevated up to 290+27% of the basal level (82.7±12 nM) [30] . It should be pointed out that the metabolites [e.g. Ins(1,4,5)P3] of phosphoinositide metabolism may not always be responsible for the PAF-induced increase in cytosolic calcium. In Kupffer cells, for example, more than 90 % of cytosolic free Ca2+ is due to extracellular Ca2+ influx rather than mobilization of Ca2+ from intracellular sites in response to PAF stimulation [93] although PAF also stimulates metabolism of phosphoinositide within the same time frame [1 18,119] . On the other hand, as a consequence of metabolism of phosphoinositide, PAF increases DAG levels [30] , stimulates protein kinase C activity [93] , and causes protein phosphorylation [30] . In an attempt to investigate the relationship between inositol lipid metabolism and the production of reactive oxygen intermediates (ROI), Huang et ai. [112] found that PAF treatment led to a rapid increase in [3H]InsP3 levels and 1,2-diacyl[3H]glycerol levels in bone marrow-derived macrophages labelled with [3H]inositol or [3H]glycerol, respectively. This response to PAF was followed by an increase in the production of ROI. Pretreatment of macrophages with phorbol ester or pertussis toxin attenuated both PAF-induced [3H]inositol phosphate production and ROI production. Phorbol ester, a protein kinase C activator, but not calcium ionophore A23 187, stimulated ROI production. It was proposed, therefore, that the DAG formed and consequent protein kinase C activation following PAF stimulation was responsible for the increased production of ROI. Protein kinase C activation also may mediate other PAF-induced cellular responses such as arachidonic acid release and eicosanoid production and protein tyrosine phosphorylation [93] .
Using a double labelling technique, Okayasu et al. [111] phosphates. In addition, a precursor-product relationship was detected between Ptdlns and lysoPtdlns in [32P]P1-labelled hepatocytes stimulated with PAF. These observations suggested that PAF stimulated the metabolism of phosphoinositides via activation of phospholipase A2 rather than via the Ptdlns cycle or a polyphosphoinositide turnover mechanism in primary cultured hepatocytes.
Calcium flux
PAF causes an elevation of cytosolic free calcium in various cells such as platelets [120, 121] , neutrophils [90, 114, 122, 123] , macrophages [30, 69, 124] , mesangial cells [111, 117] , vascular smooth muscle cells [109, 125] , endothelial cells [126] , Kupffer cells [93, 118] and neuronal cells [38] . There are at least two mechanisms involved in PAF-induced increases in cytosolic free calcium: (a) calcium influx occurs through a membraneassociated calcium channel regulated by PAF receptors or by signalling molecules generated intracellularly (e.g. metabolites of arachidonic acid) and (b) mobilization of calcium is instigated from intracellular stores in response to the intracellular second messenger InsP3 produced during PAF receptor stimulation.
Lee et al. [120, 121] first reported that PAF induced a calcium influx in rabbit platelets in a dose-dependent manner. The PAFstimulated 45Ca2+ influx in rabbit platelets could be blocked by verapamil, a calcium channel blocker, and was dependent upon extracellular [Ca2+] . Calcium mobilization was independent of cyclo-oxygenase products of arachidonic acid metabolism but was inhibited significantly by mepacrine, p-bromophenacyl bromide, eicosatetraynoic acid and nordihydroguaiaretic acid. These observations suggest that lipoxygenase-derived metabolites of arachidonic acid produced in response to PAF stimulation may mediate the PAF-induced calcium uptake in rabbit platelets [121] . In mesangial cells [117] , PAF increased cytosolic free calcium within 10 s, due to both a release of Ca2+ from intracellular storage sites as well as an influx of extracellular Ca2+. The rise in cytosolic free [Ca2+] in response to PAF stimulation was attributed to an increased production of InsP3.
In vascular smooth muscle cells, PAF stimulated the hydrolysis of phosphoinositide and a rapid efflux of 45Ca2+ from preloaded cells [109] . In an attempt to elucidate the mechanism for desensitization of the PAF response, it was demonstrated that PAF elicited a transient, dose-dependent increase in cytosolic free Ca2+ in vascular smooth muscle cells preloaded with fura-2 and an increase in InsP3 and InsP4 levels [125] . Pretreatment of the cells with PAF or PMA attenuated subsequent PAF-and angiotensin II-induced Ca2+ mobilization but not vasopressinstimulated Ca2+ mobilization. The authors proposed that both homologous and heterologous desensitization is mediated by PAF-stimulated phosphoinositide hydrolysis and DAG formation [125] . The PAF-induced increase in cytosolic free Ca2+ seemed to be independent of InsP3 since the peak of Ca2+ concentration was reached before there was a significant increase in the amount of InsP3. The effect of PAF was dependent upon extracellular calcium. In vascular endothelial cells preloaded with fura-2, however, it was demonstrated that PAF elicited an elevation of cytosolic free Ca2+ released primarily from intracellular stores [126] .
A PAF-elicited increase in cytosolic free Ca2+ in rabbit neutrophils preloaded with fura-2 was inhibited by pretreatment of the cells with fMet-Leu-Phe [123] . This finding was explained as an increased production of endogenous PAF which bound to and inactivated the PAF receptor. Pretreatment of the cells with PMA, a potent protein kinase C activator, abolished completely the rise in intracellular free Ca2+ induced by PAF. This effect of sence of an accumulation of [3H]inositol-labelled inositol PMA appeared to be mediated by protein kinase C activation, since the protein kinase C inhibitor H-7 attenuated the inhibitory effect of PMA [123] . In an attempt to assess the relative contribution of Ca2+ released from intracellular stores and Ca2+ influx from the extracellular medium to the elevation of intracellular Ca2+ during neutrophil activation, it was found that Ca2+ release from intracellular stores was rate-limiting for the PAF-and fMet-Leu-Phe-induced increase in intracellular free Ca2+ [122] .
With murine peritoneal macrophages preloaded with fura-2/AM, Prpic et al. [30] demonstrated that PAF elevated intracellular levels of Ca2+ to 290 + 27 % of basal levels (82.7 + 12 nM). Using colour-enhanced computer images of the 340nm: 380 nm fluoresence ratio of a single macrophage, Prpic showed that increases in intracellular Ca2+ were observed first in a submembranous area of the macrophage. In single mouse macrophages preloaded with fura-2, Randriamampita and Trautmann [124] observed that a pulse administration of PAF caused a biphasic increase in intracellular free [Ca2+] , including an initial transient and then a more sustained increase in intracellular Ca2+. The initial transient phase, which lasted for a few seconds, was independent of extracellular Ca2+ concentration, suggesting a release of Ca2+ from intracellular stores. The second phase of this response, which lasted for several minutes, was sensitive to extracellular Ca2+ concentrations and was probably due to an influx of Ca2+ through the plasma membrane. Also, similar biphasic responses to PAF were observed in cultured rat mesangial cells [127] . Human monocytic leukaemic U-937 cells [128] and HL-60 cells [129] , when differentiated with dimethyl sulphoxide to a macrophage-like state, express specific PAF receptors and respond to PAF stimulation by increasing their intracellular free Ca2+ levels [128] . This response to PAF depends upon extracellular Ca2+ concentrations and can be blocked by the receptor antagonist CV-3988 but not by calcium channel blockers such as nifedipine or verapamil. Both PAF-induced calcium mobilization and phosphoinositide metabolism were insensitive to pertussis toxin, but sensitive to the phospholipase C inhibitor, manoalide.
Protein tyrosine phosphorylatlon
Recent studies have demonstrated that PAF stimulates tyrosine phosphorylation of numerous cellular proteins in platelets [130, 131] , neutrophils [132] , and liver macrophages [93, 133] . PAF-induced tyrosine phosphorylation is extracellular Ca2+-dependent and may be mediated by G-protein(s) and PKC activation [93, 132] . Although it has been suggested that a tyrosine kinase is involved in the PAF-stimulated phosphoinositide turnover in platelets [130] and arachidonic acid metabolism in macrophages [71] , the molecular mechanism for the interaction between the tyrosine kinase and the phospholipases is not understood. Characterization of the tyrosine-phosphorylated proteins in platelets led to the identification of a 60 kDa phosphoprotein as the proto-oncogene product pp6oc-8rc [131] . It will be of interest to determine the functional consequence of the tyrosine phosphorylation of pp6oc-8rc protein in the PAFstimulated platelets. Also, PAF may play a role in gene expression. It was found that PAF is capable of inducing transcription of the nuclear proto-oncogenes c-fos and c-jun in B cells [134, 135] . Since the cloned PAF receptor contains several tyrosine residues in its intracellular loops and tail ( Figure 3 ) [14, 16] , it will be of interest to examine whether homologous down-regulation of PAF receptors [55] and PAF-induced protein tyrosine phosphorylation are related. Vanadate, an inhibitor of protein tyrosine phosphatase, stimulates tyrosine phosphorylation of numerous cellular proteins and induces a decrease in the number of the surface PAF receptors [133] . Both effects of vanadate can be inhibited by genistein, a putative tyrosine kinase inhibitor, suggesting that protein tyrosine phosphorylation plays a role, directly or indirectly, in the regulation of the surface expression of PAF receptors.
Hepatic actions of PAF PAF, when infused into the perfused rat liver, resulted in a several-fold increase in glucose output in the effluent perfusate [110, 136] . In contrast, when a 500-fold higher concentration of 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine or the stereoisomer 3-O-alkyl-2-acetyl-sn-glycero-1-phosphocholine was infused, no increased glycogenolysis was observed. The glycogenolytic effect of PAF depends upon both ligand and the Ca2+ concentration in the perfusate. Surprisingly, PAF failed to stimulate glycogenolysis in isolated hepatocytes although adrenaline and glucagon elicited glucose output in the same preparation [137] . In an attempt to elucidate the mechanism by which PAF causes glycogenolysis in the perfused liver, it was observed that infusion of PAF caused a transient increase in portal vein presure concomitant with the increase in glycogenolysis [138] . The vascular and metabolic responses were correlated closely, displaying similar dose dependence and similar attenuation in response to a reduction in perfusate Ca2+ concentration. The activity of glycogen phosphorylase a and the tissue ADP level were increased significantly in the perfused liver in response to PAF. Furthermore, nitric oxide, a compound which relaxes vascular smooth muscle, was found to inhibit or to abolish PAFinduced increases in portal vein pressure, oxygen consumption and, most importantly, hepatic glucose output in the perfused rat liver [139] . In contrast to its effect on PAF-induced hepatic responses, nitric oxide inhibited only the haemodynamic but not the glycogenolytic effects of phenylephrine, which acts directly on hepatocytes to induce glycogenolysis and glucose production [139] . Based on these observations, it was proposed that the glycogenolytic effect of PAF in the perfused liver was a result of the haemodynamic effects of PAF, rather than a direct effect of the agonist on the hepatocyte ( Figure 5 ). Further evidence suggested that hepatic reticuloendothelial cells, e.g. endothelial and/or Kupffer cells, may play an important role in the PAFinduced hepatic responses observed in the perfused liver: heataggregated IgG [140] , which stimulates reticuloendothelial cells in the liver, causes hepatic responses similar to those of PAF in the perfused liver; [3H]PAF infused into the perfused liver was localized specifically in small portal venules instead of in parenchymal cells [141] ; appropriately stimulated isolated Kupffer cells synthesize PAF and actively metabolize this potent phospholipid [37, 142] ; and, finally, isolated rat hepatocytes, the glycogen-storing cells in the liver, lack detectable specific PAFbinding sites (W. Chao and M. S. Olson, unpublished work).
In an effort to elucidate the important role of Kupffer cells in the hepatic actions of PAF, the specific receptor for PAF and the regulatory characteristics of the receptor have been investigated [33, 55, 56, 59] . It was found that isolated Kupffer cells possess a large number of high-affinity receptors for PAF [33] . The PAF receptor identified in Kupffer cells is functionally active since it mediates arachidonic acid release and eicosanoid production [33, 56, 59, 143] . It has been proposed that non-parenchymal cells, in response to certain stimuli, release biologically active eicosanoids which then act on parenchymal cells to stimulate glycogenolysis [144] . mediate both PAF- [143] and endotoxin- [145] stimulated glycogenolysis in the perfused liver since the cyclo-oxygenase inhibitors aspirin and indomethacin blocked the glycogenolytic action of these factors [143, 145, 184] (Figure 5 ). In addition, media obtained from aspirin-treated Kupffer cells or endothelial cells had no effect on glucose production by parenchymal cells [144] . However, this proposal has been questioned by the observation that ibuprofen (50 mM), a specific cyclo-oxygenase inhibitor, does not inhibit PAF-induced glycogenolysis and vasoconstriction significantly although it abolishes eicosanoid production in the perfused liver [85] . Nevertheless, it is probable that the hepatic glycogenolytic action of PAF observed in the perfused liver is indirect, requiring interaction between the parenchymal cells, i.e. hepatocytes, and the non-parenchymal cells, i.e. Kupffer cells and endothelial cells ( Figure 5 ). The haemodynamic and hyperglycaemic effects of PAF can be regulated by ,-adrenergic receptor stimulation [146, 147] . Infusion of isoproterenol, a fl-adrenergic receptor agonist, into the perfused rat liver attenuated the glycogenolytic stimulation caused by PAF. The regulatory effect of the fl-adrenergic agonist was believed not to be mediated by a cyclic AMP increase in ' parenchymal' cells since glucagon, which increases hepatic cyclic AMP levels to a far greater extent than does isoproterenol, had no effect on the glycogenolytic response of the liver to PAF [146] . It was suggested that the mechanism by which isoproterenol regulates the glycogenolytic effect of PAF in the perfused liver may involve interaction of the fl-agonist with non-parenchymal cells [56, 146, 147] . Further studies demonstrated that isoproterenol attenuates the subsequent PAF-stimulated biological effects, including arachidonic acid release and cyclooxygenase-derived eicosanoid production in isolated Kupffer cells. The regulatory effect of isoproterenol is highly specific and involves a fl2-adrenergic receptor-and a cyclic AMP-mediated mechanism [56] . Long-term incubation of Kupffer cells with cyclic AMP analogues or forskolin down-regulates the surface expression of PAF receptors [56] .
Ligand binding studies indicated that PAF down-regulates the surface expression of its own receptor in cultured Kupffer cells [55] . Both the rate of loss and the maximal extent of loss of the receptors were dependent upon PAF concentration. With receptor synthesis inhibited by cycloheximide in the absence of PAF, the half-life of the surface PAF receptor was about 4 h, suggesting that the turnover of the PAF receptors on the plasma membrane is continuous. Through the use of cycloheximide [55] or actinomycin D (our unpublished work), it was demonstrated that PAF receptors are not recycled and that the restoration of lost or inactivated PAF receptors requires newly synthesized protein. The fact that both cycloheximide and actinomycin D prevent the restoration of PAF receptors suggests that tissue responsiveness to PAF may be regulated by both transcription and translation. Also, surface expression of PAF receptors in Kupffer cells is down-regulated by protein kinase C activation [59, 93] . The effect of protein kinase C is specific and transient and, as a consequence, PAF-mediated arachidonic acid release and eicosanoid production are attenuated. Also, protein kinase C may be involved in the stimulatory signal transduction between the PAF receptor and the phospholipase(s) responsible for the release of arachidonic acid and subsequent production of eicosanoids. This contention is based on the observations that both down-regulation of protein kinase C and a protein kinase C inhibitor attenuate PAF-stimulated arachidonic acid release as well as eicosanoid production [59, 93] . SUMMARY During the past two decades, studies describing the chemistry and biology of PAF have been extensive. This potent phosphoacylglycerol exhibits a wide variety of physiological and pathophysiological effects in various cells and tissues. PAF acts, through specific receptors and a variety of signal transduction systems, to elicit diverse biochemical responses. Several important future directions can be enumerated for the characterization of PAF receptors and their attendant signalling mechanisms. The recent cloning and sequence analysis of the gene for the PAF receptor will allow a number of important experimental approaches for characterizing the structure and analysing the function of the various domains of the receptor. Using molecular genetic and immunological technologies, questions relating to whether there is receptor heterogeneity, the precise mechanism(s) for the regulation of the PAF receptor, and the molecular details of the signalling mechanisms in which the PAF receptor is involved can be explored. Another area of major significance is the examination of the relationship between the signalling response(s) evoked by PAF binding to its receptor and signalling mechanisms activated by a myriad of other mediators, cytokines and growth factors. A very exciting recent development in which PAF receptors undoubtedly play a role is in the regulation of the function of various cellular adhesion molecules [148, 185, 186] . Finally, there remain many incompletely characterized physiological and pathophysiological situations in which PAF and its receptor play a crucial signalling role. Our laboratory has been active in the elucidation of several tissue responses in which PAF exhibits major autocoid signalling responses, e.g. hepatic injury and inflammation [149] , acute and chronic pancreatitis [150, 151] , and cerebral stimulation and/or trauma [39] . As new experimental strategies are developed for characterizing the fine structure of the molecular mechanisms involved in tissue injury and inflammation, the essential role of PAF as a primary signalling molecule will be affirmed. Doubtless the next 20 years of experimental activity will be even more interesting and productive than the past two decades. 
